These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6604934)

  • 1. Adoptive immunotherapy of disseminated malignancies. Role of alien histocompatibility antigens on cancer cells and effectiveness of cells from alloimmunized donors.
    Tempelis LD; Wasik MR; Bortin MM
    Ric Clin Lab; 1983; 13(2):163-82. PubMed ID: 6604934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosensitization induced suppression of various murine tumors: role of non-H-2 antigens in antitumor immunity.
    Thakur VS; Seshadri M; Poduval TB; Shah DH; Sundaram K
    Indian J Exp Biol; 1990 Aug; 28(8):706-10. PubMed ID: 2253959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alien-driven diversity and alien-selected escape: a rationale for allogeneic cancer immunotherapy.
    Sondel PM; Hank JA
    Transplant Proc; 1981 Dec; 13(4):1915-21. PubMed ID: 7036482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloimmunization: induction of antileukemic reactivity without modification of anti-host reactivity in H-2-compatible mice.
    Truitt RL; Bortin MM; Rimm AA
    Transplant Proc; 1980 Mar; 12(1):143-6. PubMed ID: 6966095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive tumor immunotherapy in mice as an adjunct to whole-body x-irradiation and chemotherapy. A review.
    Fefer A
    Isr J Med Sci; 1973 Mar; 9(3):350-65. PubMed ID: 4145461
    [No Abstract]   [Full Text] [Related]  

  • 6. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor-specific immunotherapy: active immunotherapy by augmenting the induction of tumor-specific effector T cells through a T-T cell interaction mechanism].
    Kosugi A; Fujiwara H; Hamaoka T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1527-35. PubMed ID: 6236750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
    Falkenburg JH; Willemze R
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.
    Ji YH; Weiss L; Zeira M; Abdul-Hai A; Reich S; Schuger L; Slavin S
    Bone Marrow Transplant; 2003 Sep; 32(5):495-504. PubMed ID: 12942096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Frey AB; Cestari S
    Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic considerations for therapeutic strategies utilizing allogeneic hepatocytes: hepatocyte-expressed membrane-bound major histocompatibility complex class I antigen sensitizes while soluble antigen suppresses the immune response in rats.
    Scherer MN; Graeb C; Tange S; Dyson C; Jauch KW; Geissler EK
    Hepatology; 2000 Nov; 32(5):999-1007. PubMed ID: 11050050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease.
    Fontaine P; Roy-Proulx G; Knafo L; Baron C; Roy DC; Perreault C
    Nat Med; 2001 Jul; 7(7):789-94. PubMed ID: 11433342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of the graft-versus-leukemia reaction.
    Barrett AJ
    Stem Cells; 1997; 15(4):248-58. PubMed ID: 9253108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manipulation of immunologically reactive cell populations in vitro. Outline of an approach to specific immunotherapy of cancer.
    Bach ML; Bach FH; Zoschke DC
    Isr J Med Sci; 1973 Mar; 9(3):344-9. PubMed ID: 4145460
    [No Abstract]   [Full Text] [Related]  

  • 20. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
    Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
    Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.